Clinical trials
No Disease or Condition is Being Studied clinical trials
Below are recruiting no disease or condition is being studied clinical trials, each written for real people, not researchers. We’re tracking 18,433 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06687733RecruitingPhase 1/Phase 2
Gene therapy for phenylketonuria
This trial tests a new gene therapy, NGGT002, which delivers a healthy gene to help people with phenylketonuria (PKU) manage their phenylalanine levels. It may reduce the need for strict diet control.
Bengbu, AnhuiAges 18–55 - NCT06687941RecruitingPhase 1
Trial of AST-201 for GPC3-positive advanced solid tumors
This trial tests a new drug called AST-201 for people with advanced solid tumors that have a specific protein (GPC3). The study aims to see how safe and well-tolerated the drug is, and how the body processes it.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT06689085RecruitingPhase 3
Testosterone replacement study for adolescent boys with low testosterone
This trial tests a testosterone injection (XYOSTED) to see if it's safe and effective for replacing testosterone in teenage boys who have low levels due to a known medical condition. It lasts 52 weeks, with an optional 2-year follow-up.
Los Angeles, CaliforniaAges 12–17 - NCT06687590Recruiting
Serranator POINT FORCE registry for leg and dialysis access
This registry study is following patients whose blocked leg or dialysis access arteries are treated with a special balloon (Serranator) that helps open the vessel. The goal is to see how well the device works in real-world use.
Scottsdale, ArizonaAges 18 years+ - NCT06682780RecruitingPhase 1/Phase 2
Testing LM-2417 for advanced solid tumors
This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06692712RecruitingPhase 3
Gene therapy study for children with SPG50
This study tests a gene therapy called IT MELPIDA for children with SPG50, a genetic condition that affects movement and development. The treatment is given through a lumbar puncture (spinal tap) and aims to slow or stop the loss of motor skills.
Dallas, TexasAges 4 months–6 years - NCT06692738RecruitingPhase 3
Is a new immunotherapy better than Keytruda for squamous lung cancer?
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda), both combined with chemotherapy, as a first treatment for advanced squamous non-small cell lung cancer. It aims to see which combination works better.
Tucson, ArizonaAges 18 years+ - NCT06686576RecruitingPhase 3
Study of QL1706 before surgery for MSI-H colon cancer
This trial tests a new immunotherapy medicine (QL1706) given before surgery to treat colon cancer that hasn't spread yet. It's designed for patients whose tumors have a specific gene feature (MSI-H/dMMR) and who haven't had any prior treatment for this cancer.
GuangzhouAges 18–75 - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06686017Enrolling by invitation
New bone graft for lower back fusion surgery
This trial studies a new bone graft material called Virtuos for use in lower back spinal fusion surgery. It may help patients needing a one or two-level lumbar fusion by providing a safe and effective option for bone healing.
South Bend, IndianaAges 18 years+ - NCT06693336RecruitingPhase 2
Paclitaxel wafer during lung cancer surgery
This study tests a new way of giving paclitaxel—a chemotherapy drug—directly into the chest during lung cancer surgery. It aims to reduce the chance of cancer coming back after surgery, and may have fewer side effects than standard IV chemo.
Rochester, MinnesotaAges 18–80 - NCT06690775RecruitingPhase 2
Study of a new drug for platinum-resistant ovarian cancer
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06682975RecruitingPhase 1
Safety study of ZP9830 in healthy people
This study tests a new medicine called ZP9830 to see if it is safe for people and how it works in the body. Healthy volunteers aged 18 to 45 can join.
Leiden, CLAges 18–45 - NCT06684379RecruitingPhase 1/Phase 2
Two Doses of PRS CK STORM for Severe Viral Pneumonia
This study tests a new drug called PRS CK STORM to see if it can safely calm the body's overactive immune response (cytokine storm) in people with severe pneumonia from COVID-19, flu, or RSV who need oxygen. It aims to reduce inflammation and improve recovery.
Alcalá de Henares, MadridAges 18 years+ - NCT06688435RecruitingPhase 1
Immune cell therapy for hard-to-treat myasthenia gravis
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
JinanAges 18–65 - NCT06690710RecruitingPhase 1
Gene therapy injection for knee osteoarthritis
This trial tests a new gene therapy injection for knee osteoarthritis. It aims to see if the treatment is safe and if it can help with knee pain and joint function in people with moderate knee osteoarthritis.
OxfordAges 40 years+ - NCT06530550RecruitingPhase 2
PI3K inhibitor for relapsed T/NK-cell lymphoma
This trial tests a targeted therapy called a PI3K inhibitor for people whose T-cell or NK-cell lymphoma has returned or not improved after other treatments. It aims to see if the drug can shrink or control the lymphoma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06249919RecruitingPhase 1/Phase 2
Study of NS101 for sudden hearing loss
This trial tests an experimental medicine called NS101 for people who have had a sudden, severe hearing loss in one ear that did not get better with standard steroid treatment. The goal is to see if NS101 can help restore hearing better than steroids alone.
Bucheon-siAges 19–70 - NCT06617884Recruiting
Home balance training for movement disorders
This study tests a home-based walking and balance training program for people with cerebellar ataxia or Parkinson's disease. The training is done at home, so you don't need to travel. The goal is to see if this simple exercise program can improve your walking and balance.
Düsseldorf, North Rhine-WestphaliaAges 18–75 - NCT06344572Recruiting
Study of SAT-001 for children with nearsightedness
This trial tests a device called SAT-001 to slow down nearsightedness (myopia) in children aged 5 to 9. It might help if your child has mild to moderate nearsightedness with low astigmatism.
IncheonAges 5–8 - NCT06361108RecruitingPhase 1
Spray study for diabetic nerve pain in feet
This study tests a new spray medication (YJ001) applied to the feet to see if it is safe and helps reduce pain in people with diabetic peripheral neuropathy. You may qualify if you have diabetes, stable blood sugar, and moderate to severe nerve pain in your feet.
Fredericksburg, TexasAges 18–80 - NCT04442724Recruiting
MRI and bladder marker planning to guide bladder chemoradiation
This trial uses special MRI scans and tiny markers placed in the bladder to better plan bladder chemoradiation. The goal is to help target treatment more accurately and improve how well it can be delivered.
Los Angeles, CaliforniaAges 18 years+ - NCT06387069RecruitingPhase 3
Study of HMPL-306 for AML with IDH1 or IDH2 mutations
This trial tests a new drug called HMPL-306 in people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. It is for patients whose leukemia cells have a specific change in the IDH1 or IDH2 gene.
Hefei, AnhuiAges 18 years+ - NCT06650553Recruiting
Cord blood stem cell transplant for aplastic anemia
This study tests whether adding umbilical cord blood to a stem cell transplant from a half-matched donor can improve outcomes for people with severe aplastic anemia or related bone marrow failure diseases.
Taiyuan, ShanxiAges 6–75
Hear when a new No Disease or Condition is Being Studied trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for no disease or condition is being studied?
- Yes. Clin2 currently lists 18,433 recruiting no disease or condition is being studied studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a no disease or condition is being studied trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a no disease or condition is being studied trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.